500 Boylston Street, Boston, MA 02116 617-419-4700
Return to Results
The purpose of this study is to find out if treatment with BG00012 can decrease the number of MS relapses during a certain time period. Other goals of the study are to find out if, over time, BG00012 treatment can decrease the number of certain types of brain lesions commonly seen in MS patients and slow down the time it takes for your disease to get worse.
The safety of BG00012, how well you tolerate it, and the effect it may have on tests and evaluations used to assess MS are also goals of the study.
Some of the criteria for this study require the patient to be between 18-55, have a diagnosis of relapsing-remitting MS, and to have had at least one relapse in the past year.
Sponsor: Biogen Idec, Inc.
Phase: Phase 3
Trial ID: 00404
Not Accepting Healthy Volunteers